Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial

被引：0

作者：

Wang, Suyu ^{[1
]}

Zhang, Peng ^{[1
]}

机构：

[1] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8044

引用

页数：1

共 50 条

[21] A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer
Yamada, Kazuhiko
Ichiki, Masao
Takahashi, Kazuhisa
Hisamatsu, Yasushi
Takeoka, Hiroaki
Azuma, Koichi
Shukuya, Takehito
Nishikawa, Kazuo
Tokito, Takaaki
Ishii, Hidenobu
Hoshino, Tomoaki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 501 - 507
[22] Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer
Hou, Xinlei
Shi, Xueliang
Luo, Jie
ONCOLOGY LETTERS, 2022, 24 (01)
[23] A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer
Kazuhiko Yamada
Masao Ichiki
Kazuhisa Takahashi
Yasushi Hisamatsu
Hiroaki Takeoka
Koichi Azuma
Takehito Shukuya
Kazuo Nishikawa
Takaaki Tokito
Hidenobu Ishii
Tomoaki Hoshino
Cancer Chemotherapy and Pharmacology, 2016, 78 : 501 - 507
[24] Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy
Thomas A. d’Amato
Brian L. Pettiford
Mathew J. Schuchert
Ricardo Parker
William A. Ricketts
James D. Luketich
Rodney J. Landreneau
Annals of Surgical Oncology, 2009, 16 : 2848 - 2855
[25] Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy
d'Amato, Thomas A.
Pettiford, Brian L.
Schuchert, Mathew J.
Parker, Ricardo
Ricketts, William A.
Luketich, James D.
Landreneau, Rodney J.
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (10) : 2848 - 2855
[26] Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer - a pilot study
Krawczyk, Pawel
Wojas-Krawczyk, Kamila
Mlak, Radoslaw
Kucharczyk, Tomasz
Biernacka, Beata
Milanowski, Janusz
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2012, 50 (01) : 80 - 86
[27] CILENGITIDE COMBINED WITH CETUXIMAB AND PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER: SAFETY RUN-IN RESULTS OF AN OPEN-LABEL, RANDOMIZED, PHASE II (CERTO) STUDY
Vansteenkiste, J.
Waller, C.
Germonpre, P.
Bohnet, S.
Thatcher, N.
Rueeter, B.
Picard, M.
Schuette, W.
ANNALS OF ONCOLOGY, 2010, 21 : 177 - 177
[28] European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer
Novello, S
Le Chevalier, T
SEMINARS IN ONCOLOGY, 2001, 28 (04) : 3 - 9
[29] Preliminary analysis of PD-1 inhibitors combined with chemotherapy as neoadjuvant therapy for local advanced non-small cell lung cancer (NSCLC).
Li, Hongru
Yang, Xiao jie
Guo, Tianxing
Fang, Jiabin
Xu, Nengluan
Chen, Sufang
Zhang, Qiongyao
Lin, Ying
Pan, Xiaojie
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 200 - 200
[30] ERLOTINIB IN PROGRESSIVE PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II OPEN-LABEL TRIAL
Piantedosi, Francovito
Vitiello, Fabiana
Spina, Sergio
Zinno, Luigia
D'Agostino, Diego
Caputo, Francesca
Gilli, Marina
Hengeller, Mario
Iacobelli, Simona
Casale, Beniamino
Caputi, Mario
Marsico, Serafino A.
Bianco, Andrea
ANNALS OF ONCOLOGY, 2009, 20

← 1 2 3 4 5 →